Clinical Trial Update: Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating NYX-2925 for efficacy and safety in neuropathic pain due to diabetic peripheral neuropathy has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Peripheral Neuropathic Pain

Drugs mentioned

• NYX-2925

Snippet

Sponsor: Aptinyx | Conditions: Diabetic Peripheral Neuropathic Pain | Phase 2 | Status: COMPLETED | Results posted: 2023-04-28